Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 310

Similar articles for PubMed (Select 23469490)

1.

[New treatments for castration-resistant prostate cancer].

Sautois B, Gennigens C.

Rev Med Liege. 2013 Feb;68(2):94-6. French.

PMID:
23469490
2.

[Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].

Ouzaid I, Ravery V, Pouessel D, Culine S.

Prog Urol. 2013 Jan;23(1):1-7. doi: 10.1016/j.purol.2012.07.007. Epub 2012 Aug 13. Review. French.

PMID:
23287477
3.

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators.

Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.

PMID:
20888992
4.

Current clinical trials in castrate-resistant prostate cancer.

Petrylak DP.

Curr Urol Rep. 2011 Jun;12(3):173-9. doi: 10.1007/s11934-011-0187-z. Review.

PMID:
21533748
5.

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, Albiges L, Attard G, Fizazi K, De Bono JS, Massard C.

Ann Oncol. 2013 Jul;24(7):1807-12. doi: 10.1093/annonc/mdt136. Epub 2013 Apr 10.

6.

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.

van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM.

Eur J Cancer. 2013 Dec;49(18):3821-30. doi: 10.1016/j.ejca.2013.09.026. Epub 2013 Oct 24.

PMID:
24200698
7.

[Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients].

Heck MM, Höppner M, Horn T, Thalgott M, Gschwend JE, Retz M.

Urologe A. 2012 Mar;51(3):390-7. doi: 10.1007/s00120-012-2804-y. German.

PMID:
22331349
8.

New treatment options for patients with metastatic castration-resistant prostate cancer.

Higano CS.

Cancer Treat Rev. 2012 Aug;38(5):340-5. doi: 10.1016/j.ctrv.2011.07.007. Epub 2011 Sep 23.

PMID:
21944872
9.

Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.

Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ; Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.

Clin Oncol (R Coll Radiol). 2013 Jul;25(7):406-30. doi: 10.1016/j.clon.2013.03.002. Epub 2013 Apr 12. Review.

PMID:
23587782
10.

Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.

Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M.

Clin Cancer Res. 2010 Jan 1;16(1):203-11. doi: 10.1158/1078-0432.CCR-09-2514. Epub 2009 Dec 15.

11.

Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.

Ansari J, Hussain SA, Alhasso A, Mahmood R, Ansari A, Glaholm J.

Anticancer Agents Med Chem. 2011 Mar;11(3):296-306. Review.

PMID:
21426298
12.

Chemotherapy-based treatment for castration-resistant prostate cancer.

Seruga B, Tannock IF.

J Clin Oncol. 2011 Sep 20;29(27):3686-94. doi: 10.1200/JCO.2010.34.3996. Epub 2011 Aug 15. Review. Erratum in: J Clin Oncol. 2011 Dec 20;29(36):4847. Dosage error in article text.

PMID:
21844499
13.

Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.

Gallardo E, Arranz JÁ, Maroto JP, León LÁ, Bellmunt J.

Crit Rev Oncol Hematol. 2013 Nov;88(2):357-67. doi: 10.1016/j.critrevonc.2013.06.008. Epub 2013 Jul 16. Review.

PMID:
23867574
14.

[Second line therapy for castration-resistant prostate cancer (CRPC)].

Molitor B, Börgermann C.

Urologe A. 2012 Mar;51(3):357-62. doi: 10.1007/s00120-011-2758-5. Review. German.

PMID:
22113549
15.

Castration-resistant prostate cancer: systemic therapy in 2012.

Maluf FC, Smaletz O, Herchenhorn D.

Clinics (Sao Paulo). 2012;67(4):389-94. Review.

16.

Castration refractory prostate cancer: cinderella finally comes to the ball.

Chowdhury S, Harper P, Powles T.

Onkologie. 2010;33(12):655-6. doi: 10.1159/000322635. Epub 2010 Nov 29. No abstract available.

PMID:
21124035
17.

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.

Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN.

Ann Oncol. 2013 Jul;24(7):1802-7. doi: 10.1093/annonc/mdt138. Epub 2013 Apr 12.

18.

Abiraterone and its place in the treatment of metastatic CRPC.

Sartor O, Pal SK.

Nat Rev Clin Oncol. 2013 Jan;10(1):6-8. doi: 10.1038/nrclinonc.2012.202. Epub 2012 Nov 13.

PMID:
23149889
19.

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.

Paller CJ, Antonarakis ES.

Drug Des Devel Ther. 2011 Mar 10;5:117-24. doi: 10.2147/DDDT.S13029. Review. Erratum in: Drug Des Devel Ther. 2011;5:183.

20.

[The treatment of castration-resistant prostate cancer].

Petrányi Á.

Magy Onkol. 2012 Dec;56(4):219-28. doi: MagyOnkol.2012.56.4.219. Epub 2012 Oct 3. Review. Hungarian.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk